Related Experiment Video
Updated: Feb 13, 2026
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Impact of C1-Inhibitor on Renal Function and Safety Outcomes in Kidney Transplant Recipients: A Meta-Analysis of
Xinmiao Feng1, Di Zhang2, Yang Qiu1
1Department of Kidney Transplantation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background:
Complement system overactivation contributes to transplanted kidney injury in both ischemia-reperfusion and antibody-mediated rejection, ultimately affecting post-transplant renal function. C1 esterase inhibitor (C1-INH) may reduce complement-mediated injury, yet its effects on renal function and safety outcomes remain uncertain in randomized trials.
Methods:
Four RCTs were included, all focusing on the use of C1-INH in kidney transplant recipients, comparing it with control groups receiving saline. The studies were evaluated for methodological quality using the Jadad scoring system and the Cochrane Risk of Bias tool. Meta-analysis was performed using RevMan software, assessing outcomes such as renal function (eGFR), AMR incidence, and SAE occurrences.
Results:
This study included four randomized controlled trials encompassing 148 kidney transplant recipients. The findings suggest that treatment with C1-INH may be associated with an improvement in renal function, as reflected by eGFR. No statistically significant difference was observed in the incidence of delayed graft function or antibody-mediated rejection between the treatment and control groups. The overall incidence of serious adverse events was comparable between groups, with no significant differences detected in infection-related, renal, cardiovascular, or gastrointestinal events.
Conclusion:
The use of C1-INH may be associated with improved graft renal function following kidney transplantation. However, no significant benefit was observed with respect to delayed graft function or antibody-mediated rejection. The available evidence suggests an acceptable safety profile for C1-INH in this setting. Nevertheless, given the clinical heterogeneity of the included studies and the limited cumulative sample size, these findings should be interpreted as preliminary. Larger, well-designed randomized controlled trials are required to further clarify the therapeutic role of C1-INH in kidney transplantation.
Insights
Complement system overactivation can harm kidney transplants. C1 esterase inhibitor (C1-INH) may improve kidney function post-transplant, but further research is needed to confirm benefits and safety in larger trials.
Area of Science:
- Nephrology
- Transplantation Immunology
- Complement System Biology
Background:
- Complement system overactivation is a key factor in kidney transplant injury, impacting both ischemia-reperfusion and antibody-mediated rejection.
- This overactivation negatively affects post-transplant renal function.
- C1 esterase inhibitor (C1-INH) is a potential therapeutic agent to mitigate complement-mediated injury, but its efficacy and safety in kidney transplantation require further investigation.
Purpose of the Study:
- To evaluate the effects of C1 esterase inhibitor (C1-INH) on renal function and safety outcomes in kidney transplant recipients.
- To synthesize evidence from randomized controlled trials (RCTs) regarding C1-INH use in kidney transplantation.
Main Methods:
- A meta-analysis was conducted on four randomized controlled trials (RCTs) involving kidney transplant recipients.
- Studies were assessed for methodological quality using the Jadad score and Cochrane Risk of Bias tool.
- Outcomes analyzed included estimated glomerular filtration rate (eGFR), incidence of antibody-mediated rejection (AMR), delayed graft function (DGF), and serious adverse events (SAEs).
Main Results:
- The meta-analysis of four RCTs (148 recipients) suggests C1-INH treatment may be associated with improved eGFR post-kidney transplantation.
- No statistically significant differences were found in the incidence of DGF or AMR between C1-INH and control groups.
- The incidence of SAEs, including infection-related, renal, cardiovascular, and gastrointestinal events, was comparable between groups.
Conclusions:
- C1 esterase inhibitor (C1-INH) may offer a potential benefit for graft renal function following kidney transplantation.
- However, C1-INH did not demonstrate significant benefits in reducing DGF or AMR.
- While C1-INH appears to have an acceptable safety profile, the preliminary nature of these findings necessitates larger, well-designed RCTs to confirm its therapeutic role.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:45Kidney Structure
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:24Serum Studies: Renal Function Tests
01:03Drug Control Governance: Regulatory Bodies and Their Impact